This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
FIT GTU HIV vaccine
FIT Biotech Oy
Drug Names(s): GTU-MultiHIV B clade, FIT-06
Description: FIT-06 is a DNA-based therapeutic vaccine based on FIT Biotech's proprietary GTU (Gene Transport Unit) technology. FIT-06 involves a plasmid containing the regulatory HIV-1 proteins Rev, Nef, and Tat, as well as Gag p17/p24 and a stretch of cytotoxic T lymphocyte (CTL) epitope clusters from pol and env of a subtype B-HIV-1 Han-2 isolate. The plasmid also contains a nuclear anchoring protein (bovine papilloma virus E2) to ensure the long maintenance of the vector and a high expression level of the selected immunogens.
Additional information available to subscribers only: